α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Curcumin Interacts with α-Synuclein Condensates To Inhibit Amyloid Aggregation under Phase Separation

Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking - ScienceDirect

Alpha Synuclein Assay

Fast kinetics of environmentally induced α-synuclein aggregation mediated by structural alteration in NAC region and result in structure dependent cytotoxicity

Targeting Alpha-Synuclein in the Gut May Slow Down Parkinson's Disease

Parkinson's Disease – Walt Lab

Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect

Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review)

Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease

Combating Parkinson's disease

Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology